Drugs / IL-22BP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07040943 | Jun 2025 → Jul 2026 overdue | refractory malignant neoplasm | West China Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07100210 | Jan 2025 → Feb 2026 overdue | refractory malignant neoplasm | Xingchen Peng | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-22BP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07040943 ↗ |
| Action | Inhibit | “IL-22 promotes tumor progression, and its antagonist, IL-22BP, can inhibit tumor growth.” NCT07040943 ↗ |
| Route | Other | “The treatment will be administered by intratumoral injection.” NCT07040943 ↗ |